Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2003

View Archived Issues

BILS-45-BS demonstrates significant efficacy against aciclovir-resistant HSV-1

Comorbid disorders reported to reduce the response to paroxetine in OCD

Intravesical rhIL-12 in recurrent STCC of the bladder

Beneficial effects described for thymosin beta4 in septic shock

CB-300638, a thmidylate synthase inhibitor with potential as an antitumor agent

FDA approval for Crestor

Tumor necrosis therapy receives marketing approval for lung cancer in China

Phase IIIb results support use of diquafosol in dry eye

AlphaCor introduction for cornea transplant patients who reject human tissue

DakoCytomation acquires rights to H. pylori detection test

Predix and Physiome Sciences merge

BMS files IND for p38 kinase inhibitor for rheumatoid arthritis

ICN expands Kinerase license with Senetek

Q2 developments at Xoma

Angiotech: Q3 progress

NPS offers late-stage development progress report

Encysive reports on recent events

Guilford patent covers new PARP inhibitors and their use

Scientists at Sumitomo identify novel PPARdelta agonists

Takeda develops new fusion inhibitors for AIDS therapy

New hair growth-promoting agents prepared and tested at Kao

Japanese team presents new compounds with proapoptotic and cell adhesion-inhibitory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...